Evolus publishes scientific investor presentation on Evolysse hyaluronic acid filler technology

• Evolus outlined strategy to expand beyond Jeuveau with Evolysse hyaluronic acid fillers built on Symatese Cold-X manufacturing technology.
• US pivotal nasolabial fold study used split-face design with 140 subjects, comparing Evolysse Form or Evolysse Smooth versus Restylane-L, targeting non-inferiority at 6 months on WSRS.
• Primary endpoint met with statistical superiority at 6 months versus Restylane-L for both products, with 95% CI of [-0.5, -0.03] for Form, [-0.42, -0.02] for Smooth, p<0.001.
• Safety profile in study described as similar to control, with no serious adverse events reported for Form or Smooth, no delayed onset nodules reported for either product.
• Pipeline update highlighted preliminary US pivotal mid-face volume deficit study for Evolysse Sculpt versus Restylane Lyft, enrolling 304 subjects with 3:1 randomization, primary endpoint at 6 months with 24-month follow-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.